Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Active Controlled, Randomised, Parallel Group, Double Blind, Multicentre Study to Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in Europe

NCT04732793 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT04732793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Active Controlled, Randomised, Parallel Group, Double Blind, Multicentre Study to Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in Europe
Lead sponsor
LG Chem
Phase
Not applicable
Overall status
Completed
Start date
February 3, 2021
Completion date
December 7, 2021
Enrollment
284 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis (oa) of the knee